'Without the public's help we would not exist'
St Michael's Hospice in Hereford is attempting to open up a large new furniture and homeware store in Shropshire, as a way of getting extra cash.
They have revealed that more than 80% of their funding now relies on public donations - at a time when they are facing escalating costs and a rise in referrals of 119 per cent since 2017.
Chief executive Matt Fellows said: "It's a real challenge, as it is for hospices around the country at the moment."
Mr Fellows also said he was concerned that hospices face a postcode lottery when it comes to funding.
"We've got a continued cost of living pressure, and we feel that - the National Insurance changes this year alone cost us £240,000," he said.
He also added that people are living longer as a society, but not necessarily healthier.
"We're seeing people referred with greater complexity, across the UK, within palliative and end-of-life care," he said.
"It's a big struggle (to fund everything) - in round figures it costs around £12 million a year to run everything here, we get £2 million from the National Health Service so we've got to find £10 million from our community.
"We are incredibly fortunate in that they are very generous - but actually if our community stopped funding us, we would cease to exist pretty quickly."
St Michael's Hospice cared for 2,300 people last year - that's compared to just over 1,000 people in 2017.
The furniture store will be on a manufacturing site in Ludlow - a planning application is currently being considered by Shropshire Council.
In the application, it states that the hospice's services 'will be at risk' unless the plan is approved.
Mary Roche, who is 42 and lives in Hereford, is a Stage 4 lung cancer patient and has been accessing the hospice's day care services since 2023.
"It's a non-smoking lung cancer - I was diagnosed when I was 39, I coughed up a lot of blood and went for an X-ray," she said.
"I come here for counselling and to see the physio, and they've also been very good with counselling to support my family," she said.
"I come in and feel calm. I just think it's crazy that hospices are so underfunded across the country - it's just mind-boggling really."
In December hospices across England were awarded £100m of government funding over two years to improve end-of-life care.
Another £26m was promised to hospices for children and young people, which was a continuation of money previously given through a grant.
It came after hospice leaders warned they were forced to close beds due to increasing financial pressures.
Follow BBC Hereford & Worcester on BBC Sounds, Facebook, X and Instagram.
Hereford
Hospices to share £775k to upgrade facilities
Hospices in England to receive £100m funding boost
St Michael's Hospice
Hospice UK
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 days ago
- Yahoo
UK GDP growth slows but vehicle leasing powers ahead
UK GDP grew 0.3 per cent in Q2 2025, according to the Office for National Statistics (ONS) — slower than the 0.7 per cent in Q1 but ahead of forecasts. The economy contracted in April and May before bouncing back with 0.4 per cent growth in June. Liz McKeown, ONS director of economic statistics, said that while the economy was 'weak across April and May' due to activity being brought forward ahead of tax and tariff changes, it 'recovered strongly in June'. She highlighted that growth was 'led by services, with computer programming, health and vehicle leasing growing,' The Guardian reported. The inclusion of vehicle leasing among the fastest-growing service industries in Q2 has been welcomed by finance providers, who see it as a sign of sustained demand for mobility and fleet solutions. Analysts note that post-pandemic supply chain stabilisation and a shift towards flexible, asset-light business models are helping drive uptake. Mike Randall, CEO at Simply Asset Finance, said the latest GDP data comes 'against the backdrop of higher employer costs' from the recent National Insurance rise. 'Sluggish GDP growth this quarter shines a further spotlight on the business impact of National Insurance hikes,' he noted. 'As costs have increased, investing in growth and innovation has, for the time being, had to take a back seat for SMEs.' However, Randall stressed that demand remains strong: 'With recent infrastructure announcements from the Government…the potential for growth is sky high. But this requires businesses to have ready access to the right funding and support so they can strike while the iron is hot.' Business groups have warned that rising taxes and rates could weigh on momentum. The Financial Times reported that over 100 large supermarket stores could be at risk of closure under proposed business rates increases. In London, Ros Morgan of the Heart of London Business Alliance told City AM that a potential 26 per cent rise in business rates would hit firms 'with no justification or reform'. At the same time, Bloomberg has reported a shift in hiring practices, with more firms turning to self-employed contractors to avoid employers' national insurance costs. Joshua Toovey of IPSE told the outlet: 'These self-employed are a more attractive option…I can save money.' "UK GDP growth slows but vehicle leasing powers ahead" was originally created and published by Leasing Life, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Bloomberg
3 days ago
- Bloomberg
London Suffers Most Job Losses After Labour's Tax Hikes
London is bearing the brunt of the UK's jobs slowdown as a combination of tax rises, elevated wage costs and weak consumer spending force the city's business to cut payrolls faster than in the rest of the country. The capital has shed almost 45,000 payrolls since October when the Labour government announced a £26 billion ($35 billion) hike in employers' national insurance — a payroll tax — and a new higher minimum wage, according to tax data.
CNBC
3 days ago
- CNBC
Eli Lilly hikes price of diabetes drug Mounjaro in UK as Trump pressures pharma to align drug costs
Eli Lilly on Thursday said it is raising the list price of its blockbuster diabetes drug Mounjaro in the U.K. starting in September, as President Donald Trump pressures drugmakers to lower U.S. drug prices and hike them abroad. In a statement, Eli Lilly said it reached an agreement with the U.K. government to increase the list price of the weekly injection, while "maintaining access" for patients covered under the publicly funded health-care system, the National Health Service, or NHS. Eli Lilly told CNBC that the price hike will not affect the drug's availability under NHS, and it wants to work with the government to boost access. The company added that it does not determine prices that private health-care providers set, but is working with them to ensure access to Mounjaro. In a statement on Thursday, NHS said Mounjaro's list price increase "will not affect NHS commissioning of tirzepatide in England for eligible people living with obesity, based on clinical priority, or as a treatment for type 2 diabetes." Tirzepatide is the active ingredient in Mounjaro and its counterpart for weight loss, Zepbound. Mounjaro's current list price in the UK ranges from £92 (about $124.89) to £122 a month, depending on the dose size, according to Eli Lilly. The drug's new list price will increase to between £133 and £330 starting on Sept. 1. The company added that it is working with certain governments and expects to make pricing adjustments in those countries by that date. In the U.S., the list price for a month's supply of Mounjaro is $1,079.77 before insurance and other rebates. Eli Lilly said it supports the Trump administration's goal of keeping the U.S. the "world's leading destination for biopharmaceutical research and manufacturing, and the objective of more fairly sharing the costs of breakthrough medical research across developed countries." "This rebalancing may be difficult, but it means the prices for medicines paid by governments and health systems need to increase in other developed markets like Europe in order to make them lower in the US," the company said in the statement. The announcement comes after Trump in July sent separate letters to 17 drugmakers, including Eli Lilly, calling on them to take steps to lower drug prices by Sept. 29. The move built on the president's executive order in May reviving a controversial plan – the "most favored nation" policy – that aims to slash drug costs by tying the prices of some medicines in the U.S. to the significantly lower ones abroad. U.S. prescription drug prices are two-to-three times higher on average than those in other developed nations – and up to 10 times more than in certain countries, according to the Rand Corp., a public policy think tank. Trump has said he wants to narrow that gap to stop Americans from being "ripped off." Eli Lilly's announcement on Thursday comes as the industry braces for Trump's planned tariffs on pharmaceuticals imported into the U.S. In its statement, the company said it opposes those tariffs, arguing they will "raise costs, limit patient access, and undermine American leadership, especially for companies already investing heavily in domestic manufacturing." In recent months, Eli Lilly was among several drugmakers to announce new plans to invest in U.S. manufacturing sites.
